Literature DB >> 1683872

Proliferation-associated nuclear antigen p105 as a marker for metastasis of human gastric cancer.

S Ohyama1, Y Yonemura, H Kimura, T Kosaka, I Miyazaki, T Sasaki.   

Abstract

The expression of the proliferation-associated nuclear antigen p105 in 43 patients with advanced gastric carcinoma was studied by multiparameter flow cytometry. The p105 immunofluorescence intensity of tumor cells in the G0G1 phase was 1.8-14.5 times that in stromal cells, and the stromal cells could be separated by flow cytometry. The p105 intensity, which is the ratio of the mean fluorescence intensity of cancer cells to that of stromal cells in the G0G1 phase, was not correlated with the DNA index, the size of the S-phase fraction, or the histological type of the tumor. However, the intensity was significantly greater in patients with hepatic metastasis and significantly lower in patients with peritoneal metastasis. The patients with a p105 intensity of 4.0 or more had a significantly higher incidence of hepatic metastasis (8/22; 36%). The patients with a p105 intensity of less than 4.0 had a significantly higher incidence of peritoneal metastasis (8/21; 38%). These results suggest that the p105 intensity is a marker of metastasis useful in the treatment and follow-up of patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1683872     DOI: 10.1007/bf01613292

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  12 in total

1.  Assessment of cell cycle-associated antigen expression using multiparameter flow cytometry and antibody-acridine orange sequential staining.

Authors:  K D Bauer; C V Clevenger; T J Williams; A L Epstein
Journal:  J Histochem Cytochem       Date:  1986-02       Impact factor: 2.479

2.  Identification and characterization of a human proliferation-associated nucleolar antigen with a molecular weight of 120,000 expressed in early G1 phase.

Authors:  J W Freeman; R K Busch; F Gyorkey; P Gyorkey; B E Ross; H Busch
Journal:  Cancer Res       Date:  1988-03-01       Impact factor: 12.701

3.  Identification and partial characterization of a Mr 105,000 nucleolar antigen associated with cell proliferation.

Authors:  A Chatterjee; J W Freeman; H Busch
Journal:  Cancer Res       Date:  1987-12-01       Impact factor: 12.701

4.  Modulation of the nuclear antigen p105 as a function of cell-cycle progression.

Authors:  C V Clevenger; A L Epstein; K D Bauer
Journal:  J Cell Physiol       Date:  1987-03       Impact factor: 6.384

5.  Characterization of a nuclear antigen (Mr 150,000) associated with cell proliferation.

Authors:  A Chatterjee; E Durban; H Busch
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

6.  Use of immunogold electron microscopy and monoclonal antibodies in the identification of nuclear substructures.

Authors:  C V Clevenger; A L Epstein
Journal:  J Histochem Cytochem       Date:  1984-07       Impact factor: 2.479

7.  The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification.

Authors:  T Kajitani
Journal:  Jpn J Surg       Date:  1981-03

8.  Effect of differentiation on the expression of a nucleolar antigen with a molecular weight of 145,000 in HL-60 cells.

Authors:  J W Freeman; B L Dowell; R L Ochs; B E Ross; H Busch
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

9.  Induction of the nuclear protein 'cyclin' in quiescent mouse 3T3 cells stimulated by serum and growth factors. Correlation with DNA synthesis.

Authors:  R Bravo; H Macdonald-Bravo
Journal:  EMBO J       Date:  1984-12-20       Impact factor: 11.598

10.  A 57,000-mol-wt protein uniquely present in nonproliferating cells and senescent human fibroblasts.

Authors:  E Wang
Journal:  J Cell Biol       Date:  1985-02       Impact factor: 10.539

View more
  1 in total

Review 1.  Emerging evidence of the molecular landscape specific for hematogenous metastasis from gastric cancer.

Authors:  Dai Shimizu; Mitsuro Kanda; Yasuhiro Kodera
Journal:  World J Gastrointest Oncol       Date:  2018-06-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.